This is an interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration.
Interventional, prospective, randomized, comparative monocentric study aiming to evaluate the safety and efficacy of Resveratrol to reduce the progression of exudative Age-Related Macular Degeneration. Comparison of incidence of choroidal neaovascularization between each study group will be performed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
25
Dietary supplementation with Resvega BD
Dietary supplementation with resveratrol 250 mg BD
Dietary supplementation with a placebo BD
CHU de Poitiers - Ophtalmology
Poitiers, France
Comparaison of incidence of choroidal neovascularization between resveratrol group and placebo group at 24 months
What is the influence of the daily intake of 500 mg of resveratrol on the incidence of neovascularization of the second eye?
Time frame: 24 months
Comparaison of incidence of choroidal neovascularization between Resvega group and placebo group at 24 months
What is the influence of the daily intake resvega on the incidence of neovascularization of the second eye?
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.